Collegium Pharmaceutical Inc (COLL) Q1 2026 Earnings Call Transcript

Why It Matters

The results demonstrate Collegium’s ability to scale a newly acquired ADHD product while maintaining a resilient pain portfolio, positioning the firm for sustained earnings growth and stronger balance‑sheet leverage in a competitive pharmaceutical market.

Key Takeaways

• Record $780.6M revenue, up 24% YoY
• Jornay PM revenue $148.9M, 48% growth
• Net leverage below 1x, meeting target
• $980M syndicated credit facility closed, better terms
• 2026 revenue guidance $805-$825M, ~4% growth

Pulse Analysis

Collegium Pharmaceutical’s 2025 earnings underscore a rare combination of top‑line acceleration and disciplined capital management. Revenue surged to $780.6 million, propelled by a 48% jump in Jornay PM sales and modest 6% growth in the pain franchise, which includes Belbuca, Xtampza ER, and Nucynta. The company’s adjusted EBITDA climbed 15% to $460.5 million, reflecting efficient cost control despite a 37% rise in operating expenses tied to commercial expansion. This financial momentum is reinforced by robust cash generation—$329 million from operations—allowing Collegium to lower its net leverage below the 1 times target, a key metric for investors seeking low‑debt, high‑cash‑flow biopharma models.

Jornay PM emerged as the standout growth engine, capturing nearly 26% of the long‑acting branded methylphenidate market and expanding its prescriber base to over 29,000 physicians. The product’s unique evening‑dose formulation addresses a critical unmet need for symptom control upon waking, differentiating it from competitors and driving strong HCP endorsement. Digital outreach reached an additional 50,000 ADHD prescribers outside the traditional sales force, while back‑to‑school campaigns boosted quarterly prescriptions by 16%. Looking ahead, the company projects 2026 Jornay revenue of $190‑$200 million, implying more than 30% annual growth, and anticipates continued adult‑segment expansion as awareness of its differentiated dosing schedule spreads.

Strategically, the $980 million credit facility, featuring a $580 million term loan, $300 million delayed‑draw option, and $100 million revolving line, provides Collegium with low‑cost financing to fund future acquisitions and R&D while maintaining a strong liquidity cushion. The agreement with Hikma Pharmaceuticals to launch authorized generics of Nucynta further secures the pain portfolio’s cash‑flow durability amid looming generic competition. With disciplined share repurchases, a solid cash position of $386 million, and a clear growth roadmap anchored by Jornay PM, Collegium is well‑positioned to deliver incremental shareholder value and navigate the evolving pharmaceutical landscape.